7 completed, 2 unknown, 1 terminated. 4 Not applicable, 3 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 4 | Completed 3, Unknown 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Buffers: new trials by email Literature Review of Buffers trials Research Report on Buffers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults NTS-104 TRIS, Placebo - Acute Ischemic Stroke | Phase 1 | Terminated | NeuroTrauma Sciences, LLC | 48 | 2023-05-01 | 2026-07-24 |
| Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19 INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer - Coronavirus Infection, SARS-CoV 2 | Phase 1 / Phase 2 | Completed | International Vaccine Institute | 79 | 2020-07-15 | 2022-07-18 |
| A Study of Lidocaine Pertubation as a Treatment for Unexplained Infertility Isifera+, Buffer - Unexplained Infertility | Phase 2 | Unknown | Isifer AB | 120 | 2017-06-20 | 2017-12-29 |
| Pain Perception: Lidocaine Rate/Temp/Buffer Slow, Room Temperature Injection, Rapid, Room Temperature Injection, Slow, Warm Temperature Injection - Pain | Not applicable | Unknown | Northwestern University | 26 | 2016-06-01 | 2024-03-15 |
| A Pilot Evaluation of Adhesives and How They Are Impacted by Out-put Buffer, Own output, simulated output - Ileostomy | Not applicable | Completed | Coloplast A/S | 4 | 2015-11-01 | 2016-01-20 |
| Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5) Thrombosomes, Placebo - Healthy | Early Phase 1 | Completed | Cellphire Therapeutics, Inc. | 15 | 2014-09-01 | 2017-12-13 |
| Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh Buffer - Polio | Not applicable | Completed | Johns Hopkins Bloomberg School of Public Health | 300 | 2012-04-01 | 2013-04-25 |
| Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome 2% sodium chondroitin sulfate, Placebo - Interstitial Cystitis, Painful Bladder Syndrome | Phase 2 | Completed | Watson Pharmaceuticals | 98 | 2009-07-01 | 2013-05-03 |
| Low-dose Challenge Model With Enterotoxigenic E Coli E coli strain H10407 and buffer, E coli H10407 and buffer - Diarrhea | Phase 1 | Completed | Johns Hopkins Bloomberg School of Public Health | 30 | 2009-02-01 | 2014-09-12 |
| Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain B-TCP + 0.3 mg/ml rhPDGF-BB in buffer, B-TCP + 1.0 mg/ml rhPDGF-BB in buffer, B-TCP +buffer - Periodontitis | Not applicable | Completed | University of Michigan | 180 | 2000-01-01 | 2016-01-08 |
Coronavirus Infections (1) · Cystitis, Interstitial (1) · Diarrhea (1) · Ischemic Stroke (1) · Pain (1) · Periodontitis (1) · Poliomyelitis (1)
Johns Hopkins Bloomberg School of Public Health (2) · Cellphire Therapeutics, Inc. (1) · Coloplast A/S (1) · International Vaccine Institute (1) · Isifer AB (1) · NeuroTrauma Sciences, LLC (1) · Northwestern University (1) · University of Michigan (1) · Watson Pharmaceuticals (1)
United States (6) · Bangladesh (1) · Denmark (1) · Poland (1) · South Korea (1)
Clayton Harro, M.D. (1) · Eu Suk Kim, MD (1) · Jack Spira, Md PhD (1) · Lawrence A Hill, PharmD, MBA (1) · Lene F Nielsen, MSc (1) · Marc de Somer, MD (1) · Michael Fitzpatrick, PhD (1) · Murad Alam, MD (1) · Myoung-don Oh, MD (1) · Neal A Halsey, MD (1) · Sherrill Slichter, MD (1) · William Giannobile, DDS, DMedSc (1)
PMID 16332231, PMID 18281242, PMID 21852546, PMID 22612364, PMID 25316860, PMID 29702652